Supplementary Figure S4 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

This is a RCT study (also classified as: Phase 2).

Key Points

Tumor regression was observed in response to treatment with durvalumab and tremelimumab.
Key findings highlight necrosis and residual viable tumor were noted, indicating mixed responses.
The study utilized a phase II open-label randomized clinical trial design to evaluate treatment effects.
These results suggest potential benefits of immunotherapy, though variability in treatment responses exists.

Open-label randomized clinical trial assessed treatment response in head and neck squamous cell carcinoma, indicating potential efficacy.

No takes yet. Share an insight, caveat, or question.

Kim et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share